REGENXBIO Inc. (RGNX) stock
RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.24−0.08 (-1.09%)
Close on Nov 17, 2026Market cap $477.94MP/E –Yield –
Regenxbio EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Regenxbio's EPS for the twelve months ending Jun 30, 2026 was -$3.79. For fiscal 2025 it was -$3.76. The highest annual figure on record is $2.91 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$3.76 | – |
| FY2024 | Dec 31, 2024 | -$4.59 | – |
| FY2023 | Dec 31, 2023 | -$6.02 | – |
| FY2022 | Dec 31, 2022 | -$6.50 | -323.4% |
| FY2021 | Dec 31, 2021 | $2.91 | – |
| FY2020 | Dec 31, 2020 | -$2.98 | – |
| FY2019 | Dec 31, 2019 | -$2.58 | -194.5% |
| FY2018 | Dec 31, 2018 | $2.73 | – |
| FY2017 | Dec 31, 2017 | -$2.45 | – |
| FY2016 | Dec 31, 2016 | -$2.38 | – |
| FY2015 | Dec 31, 2015 | -$2.59 | – |
| FY2014 | Dec 31, 2014 | -$1.82 | – |
| FY2013 | Dec 31, 2013 | -$2.50 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0.43 | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.72 | -1533.3% |
| Q4 FY2025 | Dec 31, 2025 | -$1.30 | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.20 | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.38 | – |
| Q1 FY2025 | Mar 31, 2025 | $0.12 | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.01 | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.17 | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.05 | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.38 | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.43 | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.41 | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.66 | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.53 | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.75 | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.58 | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.79 | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.37 | -695.7% |
| Q2 FY2021 | Jun 30, 2021 | -$1.36 | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.20 | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.24 | – |
| Q3 FY2020 | Sep 30, 2020 | $0.23 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.91 | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.08 | – |
| Q4 FY2019 | Dec 31, 2019 | -$0.72 | -754.5% |
| Q3 FY2019 | Sep 30, 2019 | -$0.94 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.04 | -113.3% |
| Q1 FY2019 | Mar 31, 2019 | -$0.89 | -129.3% |
| Q4 FY2018 | Dec 31, 2018 | $0.11 | – |
| Q3 FY2018 | Sep 30, 2018 | -$0.56 | – |
| Q2 FY2018 | Jun 30, 2018 | $0.30 | – |
| Q1 FY2018 | Mar 31, 2018 | $3.04 | – |
| Q4 FY2017 | Dec 31, 2017 | -$0.51 | – |
| Q3 FY2017 | Sep 30, 2017 | -$0.67 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.47 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.82 | – |
| Q4 FY2016 | Dec 31, 2016 | -$0.74 | – |
| Q3 FY2016 | Sep 30, 2016 | -$0.69 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?